Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Hal Brown

Family Medicine Vero Beach, FL Medical Doctor

NPI 1902804677 CMS profile 267406

1265 36Th St, Vero Beach, FL 32960

Open in the dashboard

General payments

$477,389

220 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

6 holdings reported · through program year 2025

Through program year 2025, Hal Brown of Vero Beach, FL is reported in the CMS Open Payments database as having received $477,389 across 220 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $0 across 6 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $140,141 4
2024 General $60,163 4
2023 General $234 4
2022 General $27 1
2021 General $273,274 7
2020 General $1,487 80
2019 General $2,063 120
2025 Ownership $0 3
2024 Ownership $0 1
2023 Ownership $0 1
2020 Ownership $0 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hal Brown
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Hal Brown were reported at $140,141. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Hal Brown Family Medicine median Middle half National median
2019 $2,063 $150 $41–$543 $163
2020 $1,487 $120 $32–$415 $114
2021 $273,274 $137 $35–$551 $132
2022 $27 $137 $37–$512 $149
2023 $234 $149 $42–$545 $160
2024 $60,163 $156 $44–$560 $164
2025 $140,141 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Swan Valley Medical Incorporated $473,196 6 payments
  2. Amgen Inc. $453 25 payments
  3. Pfizer Inc. $445 25 payments
  4. Novo Nordisk Inc $409 32 payments
  5. GlaxoSmithKline, LLC. $355 14 payments
  6. Novartis Pharmaceuticals Corporation $348 17 payments
  7. Amarin Pharma Inc. $335 18 payments
  8. Boston Scientific Corporation $218 3 payments
  9. AstraZeneca Pharmaceuticals LP $201 11 payments
  10. Merck Sharp & Dohme Corporation $196 13 payments
  11. Other $1,233 56 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $413,000 4 payments
  2. Grant $60,000 1 payment
  3. Food and Beverage $4,129 212 payments
  4. Travel and Lodging $196 1 payment
  5. Gift $50 1 payment
  6. Education $14 1 payment
Products named General payments · program years 2019–2025
  1. Ozempic $332 28 payments
  2. ENTRESTO $326 16 payments
  3. AIMOVIG $224 12 payments
  4. Repatha $221 12 payments
  5. INJECTAFER $190 7 payments
  6. Vascepa $188 10 payments
  7. Prolia $180 10 payments
  8. COLOGUARD $172 10 payments
  9. PNEUMOVAX 23 $167 11 payments
  10. EVENITY $164 10 payments
  11. Other $3,442 176 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 40 drugs

Part D claims

1,448

Median for Family Practice: 1,826

Drug cost

$102,242

Median for Family Practice: $120,094

Branded share of claims

8.8%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 30 $44,109
Ozempic Semaglutide Brand 21 $24,548
Myrbetriq Mirabegron Brand 17 $11,806
Atorvastatin Calcium Generic 231 $2,964
Rosuvastatin Calcium Generic 141 $2,949
Levothyroxine Sodium Generic 75 $1,208
Ezetimibe Generic 31 $1,183
Valsartan Generic 35 $1,170
Bupropion Xl Bupropion Hcl Brand 12 $1,037
Tamsulosin Hcl Generic 36 $775

The 10 drugs with the highest cost, of 40 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Veozah
  • Astellas Pharma US Inc $125
$125 — —
VRAYLAR
  • AbbVie, Inc. $38
$38 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

220 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record